Drug firms overcharged Rs 2,700 cr
- Elections 2014 Live: Sonia Gandhi, Arvind Kejriwal cast their votes in third phase of LS polls
- Modi tukde tukde kar dega... ladaa dega, says Rahul
- Congress not aggressive enough, says Sharad Pawar
- NSCN (IM) takes over Manipur booths, loads EVMs with votes
- Narendra Modi mentions wife Jashodaben in poll affidavit for first time
Pharmaceutical companies have overcharged customers a total of more than Rs 2,700 crore of which Cipla alone owes the government approximately Rs 1,700 crore. Less than 10 per cent of the money has been recovered by National Pharmaceutical Pricing Authority and Department of Pharmaceuticals with the big pharmas dragging the government to court and not paying up, citing the sub-judice status of the cases.
The Department of Pharmaceuticals in its reply to a question in the Lok Sabha Tuesday gave out details of the money that the companies owe the government in 125 separate cases of overcharging pending in the Supreme Court and lower courts. The NPPA has recovered about Rs 198 crore so far, most of it from smaller companies.
Cases of overcharging start either on complaints by consumers, which are not very frequent, or when the NPPA detects a marked-up MRP on samples it lifts from market.
Last year, a survey by the Corporate Affairs Ministry found that despite NPPA pricing regulations that seals the profit margin of drug companies at 100 per cent over the cost of production (COP), mark-ups of 200-500 per cent were detected in 21 common drugs, the highest being 1,122 per cent for a drug manufactures by Glaxo Smithkline.
According to the figures, the Centre's dues from individual drugs that have been sold for a higher price include a Rs 553 crore over recovery from a Salbutamol formulation (asthma drug), Rs 357 crore for a second generation antibiotic Ciprofloxacin and Rs 453 crore from a norfloxacin-based drug — all from Cipla.
The firm has not the money back to the government. It's spokesperson refused to talk about it saying the matter was sub-judice.
Some of the other companies facing allegations of overcharging adding up to several crores and with nil recovery include Claris Life Science that overcharged to the tune of Rs 104 crore for its Eye V Fluid, Okasa Pharma which sold Norfloxacin at higher prices and raised Rs 93.22 crore, Cadila Healthcare that overcharged a total of Rs 17 crore on asthma medication Deriphyllin, and Ranbaxy that earned Rs 61 crore extra from the sale of Ciprofloxacin by violating price lists.
- Neemu Bhoumik seeks LS entry; people’s issues, Raiganj roots in mind
- Another Bittu, Simerjit file papers as Independents
- Firing at district food and civil supplies office, one injured
- Day after stand-off with EC, Didi vows ‘revenge’ over ‘insult’ by Delhi
- ‘Hate’ speech: Amit Shah moves HC for stay on arrest, quashing of FIRs
- Adarsh Shastri ‘covers’ for AAP’s Jaaferi